Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Testicular cancer incidence predictions in Europe 2010–2035: A rising burden despite population ageing

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

APA

CBE

MLA

Vancouver

Author

Znaor, Ariana ; Skakkebæk, Niels E. ; Rajpert-De Meyts, Ewa ; Laversanne, Mathieu ; Kuliš, Tomislav ; Gurney, Jason ; Sarfati, Diana ; McGlynn, Katherine A. ; Bray, Freddie. / Testicular cancer incidence predictions in Europe 2010–2035 : A rising burden despite population ageing. In: International Journal of Cancer. 2019.

Bibtex

@article{035557f31aec42509ae28a3b71e20a8a,
title = "Testicular cancer incidence predictions in Europe 2010–2035: A rising burden despite population ageing",
abstract = "Testicular cancer is the most common cancer among young men of European ancestry, with about one-third of all cases occurring in Europe. With the historically increasing trends in some high-incidence populations reported to have stabilised in recent years, we aimed to assess recent trends and predict the future testicular cancer incidence burden across Europe. We extracted testicular cancer (ICD-10 C62) incidence data from Cancer Incidence in Five Continents Volumes VII–XI and complemented this with data published by registries from 28 European countries. We predicted cancer incidence rates and the number of incident cases in Europe in the year 2035 using the NORDPRED age-period-cohort model. Testicular cancer incidence rates will increase in 21 out of 28 countries over the period 2010–2035, with trends attenuating in the high-incidence populations of Denmark, Norway, Switzerland and Austria. Although population ageing would be expected to reduce the number of cases, this demographic effect is outweighed by increasing risk, leading to an overall increase in the number of cases by 2035 in Europe, and by region (21, 13 and 32% in Northern, Western and Eastern Europe, respectively). Declines are however predicted in Italy and Spain, amounting to 12% less cases in 2035 in Southern Europe overall. In conclusion, the burden of testicular cancer incidence in Europe will continue to increase, particularly in historically lower-risk countries. The largest increase in the number of testicular cancer patients is predicted in Eastern Europe, where survival is lower, reinforcing the need to ensure the provision of effective treatment across Europe.",
keywords = "age-period-cohort, Europe, incidence, predictions, testicular cancer",
author = "Ariana Znaor and Skakkeb{\ae}k, {Niels E.} and {Rajpert-De Meyts}, Ewa and Mathieu Laversanne and Tomislav Kuli{\v s} and Jason Gurney and Diana Sarfati and McGlynn, {Katherine A.} and Freddie Bray",
year = "2019",
month = jan,
day = "1",
doi = "10.1002/ijc.32810",
language = "English",
journal = "Acta - Unio Internationalis Contra Cancrum",
issn = "0020-7136",
publisher = "John/Wiley & Sons, Inc. John/Wiley & Sons Ltd",

}

RIS

TY - JOUR

T1 - Testicular cancer incidence predictions in Europe 2010–2035

T2 - A rising burden despite population ageing

AU - Znaor, Ariana

AU - Skakkebæk, Niels E.

AU - Rajpert-De Meyts, Ewa

AU - Laversanne, Mathieu

AU - Kuliš, Tomislav

AU - Gurney, Jason

AU - Sarfati, Diana

AU - McGlynn, Katherine A.

AU - Bray, Freddie

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Testicular cancer is the most common cancer among young men of European ancestry, with about one-third of all cases occurring in Europe. With the historically increasing trends in some high-incidence populations reported to have stabilised in recent years, we aimed to assess recent trends and predict the future testicular cancer incidence burden across Europe. We extracted testicular cancer (ICD-10 C62) incidence data from Cancer Incidence in Five Continents Volumes VII–XI and complemented this with data published by registries from 28 European countries. We predicted cancer incidence rates and the number of incident cases in Europe in the year 2035 using the NORDPRED age-period-cohort model. Testicular cancer incidence rates will increase in 21 out of 28 countries over the period 2010–2035, with trends attenuating in the high-incidence populations of Denmark, Norway, Switzerland and Austria. Although population ageing would be expected to reduce the number of cases, this demographic effect is outweighed by increasing risk, leading to an overall increase in the number of cases by 2035 in Europe, and by region (21, 13 and 32% in Northern, Western and Eastern Europe, respectively). Declines are however predicted in Italy and Spain, amounting to 12% less cases in 2035 in Southern Europe overall. In conclusion, the burden of testicular cancer incidence in Europe will continue to increase, particularly in historically lower-risk countries. The largest increase in the number of testicular cancer patients is predicted in Eastern Europe, where survival is lower, reinforcing the need to ensure the provision of effective treatment across Europe.

AB - Testicular cancer is the most common cancer among young men of European ancestry, with about one-third of all cases occurring in Europe. With the historically increasing trends in some high-incidence populations reported to have stabilised in recent years, we aimed to assess recent trends and predict the future testicular cancer incidence burden across Europe. We extracted testicular cancer (ICD-10 C62) incidence data from Cancer Incidence in Five Continents Volumes VII–XI and complemented this with data published by registries from 28 European countries. We predicted cancer incidence rates and the number of incident cases in Europe in the year 2035 using the NORDPRED age-period-cohort model. Testicular cancer incidence rates will increase in 21 out of 28 countries over the period 2010–2035, with trends attenuating in the high-incidence populations of Denmark, Norway, Switzerland and Austria. Although population ageing would be expected to reduce the number of cases, this demographic effect is outweighed by increasing risk, leading to an overall increase in the number of cases by 2035 in Europe, and by region (21, 13 and 32% in Northern, Western and Eastern Europe, respectively). Declines are however predicted in Italy and Spain, amounting to 12% less cases in 2035 in Southern Europe overall. In conclusion, the burden of testicular cancer incidence in Europe will continue to increase, particularly in historically lower-risk countries. The largest increase in the number of testicular cancer patients is predicted in Eastern Europe, where survival is lower, reinforcing the need to ensure the provision of effective treatment across Europe.

KW - age-period-cohort

KW - Europe

KW - incidence

KW - predictions

KW - testicular cancer

UR - http://www.scopus.com/inward/record.url?scp=85077618809&partnerID=8YFLogxK

U2 - 10.1002/ijc.32810

DO - 10.1002/ijc.32810

M3 - Journal article

C2 - 31773729

AN - SCOPUS:85077618809

JO - Acta - Unio Internationalis Contra Cancrum

JF - Acta - Unio Internationalis Contra Cancrum

SN - 0020-7136

ER -

ID: 59193938